See article, p. 47.
RAS/ERK pathway inhibitors are used frequently in NSCLC therapy, yet how they affect the tumor immune microenvironment has remained unclear. Tang, Li, and colleagues studied the immunomodulatory effects of SHP2 inhibitors, recently shown to be active against select KRAS-mutant tumors. SHP2 inhibitors depleted alveolar and M2-like macrophages and promoted B and T lymphocyte infiltration, all salutary therapeutic effects. However, they also increased intratumor gMDSCs via tumor-intrinsic, NFκB-dependent production of CXCR2 ligands. Other RAS/ERK pathway inhibitors had similar effects in mouse and human models. Combined SHP2/CXCR1/2 inhibition depleted a specific gMDSC subset, reactivated select antitumor T cells, and improved survival.
See article, p. 62.
Persistent COVID-19 infection in patients with cancer has been reported, but the drivers of this clinical phenomenon are unknown. Lee and colleagues report that B-cell lymphomas were at particularly high risk for persistent SARS-CoV-2 positivity. Further analysis of these patients...
RSS Feeds